Основная статистика
| CIK | 1621221 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Artelo Biosciences Inc - Warrants (18/06/2024)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| September 10, 2025 |
CERTIFICATE OF AMENDMENT TO BYLAWS OF ARTELO BIOSCIENCES, INC. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO BYLAWS OF ARTELO BIOSCIENCES, INC. 1. A new Section 9.3 is added to the Bylaws consisting of the following: In accordance with subsections 2 and 3 of NRS 78.378, the Company shall in all respects be considered an “issuing corporation” for purposes of the provisions of NRS 78.378 to 78.3793, inclusive, irrespective of whether the Company, as of any date, (i) |
|
| September 5, 2025 |
640,924 Shares of Common Stock Pre-Funded Warrants to Purchase up to 40,894 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (to Prospectus dated July 14, 2023) 640,924 Shares of Common Stock Pre-Funded Warrants to Purchase up to 40,894 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, Artelo Biosciences, Inc. (the “Company,” “Artelo,” “Artelo Biosciences,” “we,” “us,” and “our”) is offering 64 |
|
| September 5, 2025 |
Artelo Biosciences Announces Closing of $3.0 Million Public Offering EXHIBIT 99.3 Artelo Biosciences Announces Closing of $3.0 Million Public Offering SOLANA BEACH, CA – September 5, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of it |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| September 5, 2025 |
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering EXHIBIT 99.2 Artelo Biosciences Announces Pricing of $3.0 Million Public Offering SOLANA BEACH, CA – September 4, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of it |
|
| September 5, 2025 |
EXHIBIT 1.1 640,924 SHARES OF COMMON STOCK AND 40,894 PRE-FUNDED WARRANTS ARTELO BIOSCIENCES, INC. UNDERWRITING AGREEMENT September 4, 2025 R. F. Lafferty & Co., Inc. 40 Wall Street, 27th Floor New York, NY 10005 As the Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, Artelo Biosciences, Inc., a company incorporated under the law |
|
| September 5, 2025 |
Artelo Biosciences Announces Proposed Underwritten Public Offering EXHIBIT 99.1 Artelo Biosciences Announces Proposed Underwritten Public Offering SOLANA BEACH, CA – September 3, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an |
|
| September 5, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: September [], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| September 4, 2025 |
Up to $3,451,527 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Up to $3,451,527 Shares of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025 (the “ATM Prospectus”), relating to the offer and sale of up to $6,500,000 shares of our common stock, $0.001 par value per s |
|
| September 4, 2025 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 4, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell and are |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 3, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| August 20, 2025 |
TERMINATION AND MUTUAL RELEASE AGREEMENT EXHIBIT 10.1 TERMINATION AND MUTUAL RELEASE AGREEMENT This Termination and Mutual Release Agreement (the “Agreement”) is entered into as of the date that the last Party executes this Agreement (the “Effective Date”), by and among ARTELO BIOSCIENCES, INC., a Nevada corporation (the “Company”), and the purchasers listed on the signature pages hereto (each, an “Investor,” and collectively, the “Inves |
|
| August 20, 2025 |
EXHIBIT 10.2 TERMINATION AGREEMENT TERMINATION AGREEMENT, dated August 19, 2025 (the “Termination Agreement”), by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the “Company”) and ABK LABS, INC., a Delaware corporation (“Consultant”). Each of the Company and Consultant are referred to in this Termination Agreement individually as a “Party” and, collectively, as the “Parties.” RECITALS |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| August 7, 2025 |
EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into effective as of August 1, 2025 (the “Effective Date”) by and between Artelo Biosciences, Inc., 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075, a Nevada Corporation (the “Company”), and ABK Labs, Inc., a Delaware corporation (“Consultant”). 1. Services. During the term of this Agreement, Consultant |
|
| August 7, 2025 |
Common Stock Warrant issued to ABK Labs, Inc., dated August 1, 2025 EXHIBIT 4.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH [***]. NEITHER THIS SECURITY NOR ANY SECURITIES WHICH MAY BE ISSUED UPON EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| August 4, 2025 |
EXHIBIT 99.2 Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution o |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2025 |
EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 4, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 4, 2025 |
EXHIBIT 99.1 Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway. SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, |
|
| August 4, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 1, 2025, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). WHEREAS, subject to the terms and conditions set |
|
| August 4, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| July 18, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (to Prospectus dated July 7, 2023) $6,500,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $6.50 million, from time to time solely through R.F. Lafferty & Co., Inc., as exclusive sales a |
|
| July 18, 2025 |
EXHIBIT 1.1 AT THE MARKET OFFERING AGREEMENT Up to $6,500,000 Shares of Common stock July 18, 2025 R.F. Lafferty & Co., Inc. 40 Wall Street, 29th Floor New York, NY 10005 Ladies and Gentlemen: Artelo Biosciences, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with R.F. Lafferty & Co., Inc. (the “Manager”) as follows: 1. Definitions |
|
| July 18, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 16, 2025 |
July 16, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: Artelo Biosciences Inc. Registration Statement on Form S-1 File No. 333-288653 Acceleration Request Requested Date: July 17, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as pract |
|
| July 11, 2025 |
Calculation of Filing Fee Table EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| July 11, 2025 |
ARTELO BIOSCIENCES, INC. Consolidated Balance Sheets (In thousands, except share data) EXHIBIT 99.2 Unaudited Interim Financial Statements Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 2 Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024 3 Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2025 and 2024 4 Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS EXHIBIT 99.1 ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 206). 2 Consolidated Balance Sheets at December 31, 2024 and 2023. 3 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023. 4 Consolidated Statements of Stockholders’ Equity for the years ended Decem |
|
| June 26, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 26, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 26, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 24, 2025, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). WHEREAS, subject to the terms and conditions set f |
|
| June 26, 2025 |
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing EXHIBIT 99.1 Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing SOLANA BEACH, CA – June 26, 2025 – Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced it has entered into |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 26, 2025 |
EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 13, 2025 |
EXHIBIT 3.1 |
|
| June 13, 2025 |
EXHIBIT 99.1 June 11, 2025 Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025 SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid- signaling pathways to develop treatments for people living with cancer, pain, derma |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| May 1, 2025 |
EXHIBIT 10.1 NOTE AND WARRANT SUBSCRIPTION AGREEMENT This Note and Warrant Subscription Agreement (this “Agreement”) is entered into by and between Artelo Biosciences, Inc., a Nevada corporation (the “Company”) and the Investors listed on Schedule A hereto and shall be effective as of the “Effective Date” as shown on the Company’s signature page hereto. RECITALS A. The Company’s Board of Directors |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| May 1, 2025 |
EXHIBIT 10.2 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REG |
|
| May 1, 2025 |
EXHIBIT 10.3 NEITHER THIS SECURITY NOR ANY SECURITIES WHICH MAY BE ISSUED UPON EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY U.S. STATE OR OTHER JURISDICTION OR ANY EXCHANGE OR SELF-REGULATORY ORGANIZATION, IN RELIANCE UPON EXEMPTIONS FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS A |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 20, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 3, 2025 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock. Description of Capital Stock The following description of our capital stock is a summary and does no |
|
| March 3, 2025 |
Insider Trading Policy, as amended EXHIBIT 19.1 ARTELO BIOSCIENCES, INC. INSIDER TRADING POLICY (Adopted on August 18, 2023) A. POLICY OVERVIEW Artelo Biosciences, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its o |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2024 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTE |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 29, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| March 25, 2024 |
EXHIBIT 97.1 ARTELO BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on November 17, 2023 Artelo Biosciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay |
|
| March 25, 2024 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock and warrants. Description of Capital Stock The following description of our capital stock is a summ |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2024 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTE |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2023 |
July 12, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dillon Hagius Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on July 6, 2023 File No. 333-273153 Acceleration Request Requested Date: July 14, 2023 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 |
|
| July 7, 2023 |
July 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 6, 2023 |
As filed with the Securities and Exchange Commission on July 6, 2023 As filed with the Securities and Exchange Commission on July 6, 2023 Registration No. |
|
| July 6, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) ARTELO BIOSCIENCES, INC. |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| May 11, 2023 |
Articles of Incorporation, as amended EXHIBIT 3.1 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| April 21, 2023 |
As filed with the Securities and Exchange Commission on April 21, 2023 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. |
|
| April 21, 2023 |
EXHIBIT 3.1 BYLAWS OF ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS 1.1 Annual Meeting. The annual meeting of the shareholders of Artelo Biosciences, Inc. (the "Corporation") for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at the principal office of the corporation, or at some |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2023 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock and warrants. Description of Capital Stock The following description of our common stock is a summa |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| November 8, 2022 |
EXHIBIT 21.1 Subsidiaries of Artelo Biosciences, Inc. Jurisdiction of Incorporation Artelo Biosciences Limited United Kingdom Artelo Biosciences Corporation Canada |
|
| November 8, 2022 |
EXHIBIT 3.3 BYLAWS OF ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS 1.1 Annual Meeting. The annual meeting of the shareholders of Artelo Biosciences, Inc. (the "Corporation") for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at the principal office of the corporation, or at some |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIO |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIEN |
|
| August 9, 2022 |
Certificate of Change, effective August 9, 2022 EXHIBIT 3.1 |
|
| August 9, 2022 |
EXHIBIT 99.1 Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 2022 SOLANA BEACH, Calif., Aug |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2022 |
ARTELO BIOSCIENCES, INC. 15,000,000 Shares of common stock 424B3 1 artl424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-264967 PROSPECTUS ARTELO BIOSCIENCES, INC. 15,000,000 Shares of common stock This prospectus relates to the offer and sale from time to time of up to 15,000,000 shares of common stock, par value $0.001 per share, of Artelo Biosciences, Inc., a Nevada corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park, re |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy Stateme |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| May 26, 2022 |
May 26, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Dillon Hagius Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 File No. 333-264967 Acceleration Request Requested Date: May 31, 2022 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| May 16, 2022 |
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 13, 2022, is made by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein |
|
| May 16, 2022 |
As filed with the Securities and Exchange Commission on May 16, 2022 As filed with the Securities and Exchange Commission on May 16, 2022 Registration No. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy Statement D |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2022 |
Articles of Incorporation, as amended EXHIBIT 3.1 |
|
| May 16, 2022 |
EXHIBIT 107 Filing Fee Table Title of each class of securities to be registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share (2) Proposed maximum aggregate offering price Amount of registration fee Shares of common stock of Common Stock, par value $0. |
|
| May 16, 2022 |
Purchase Agreement between the Company and Lincoln Park Capital Fund, LLC, dated May 13, 2022. EXHIBIT 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of May 13, 2022, is made by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIE |
|
| April 7, 2022 |
EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, $0. |
|
| April 7, 2022 |
As filed with the Securities and Exchange Commission on April 7, 2022 As filed with the Securities and Exchange Commission on April 7, 2022 Registration No. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from September 1, 2021 to December 31, 2021 Commission file number 001-38951 Artel |
|
| March 21, 2022 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), our common stock. Description of Capital Stock The following description of our common stock is a summary and does not |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 10, 2022 |
EXHIBIT 3.1 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| February 23, 2022 |
ARTL / Artelo Biosciences Inc / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2022 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) CUSIP No.: 04301G201 Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.001 per share of Artelo Biosciences, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate |
|
| February 9, 2022 |
ARTL / Artelo Biosciences Inc / Parian Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2022 |
ARTL / Artelo Biosciences Inc / Hudson Bay Capital Management LP - ARTL 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 3, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| November 29, 2021 |
EXHIBIT 3.4 |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Biosciences, Inc. ( |
|
| November 29, 2021 |
EXHIBIT 3.5 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 16, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 15, 2021 |
EXHIBIT 3.1 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIENC |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| May 7, 2021 |
DEF 14A 1 artldef14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6 |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| April 9, 2021 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement 8-K 1 artl8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of in |
|
| April 9, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235917 PROSPECTUS SUPPLEMENT (to Prospectus dated February 3, 2020) $20,500,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $20.5 million, from time to time solely through Ladenburg Thalmann & Co. Inc., as exclusiv |
|
| April 9, 2021 |
At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc. EXHIBIT 10.1 Artelo Biosciences, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement April 9, 2021 Ladenburg Thalmann & Co. Inc. 640 5th Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Artelo Biosciences, Inc., a Nevada corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc. (the ?Agent?) as follows: 1. Issu |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 9, 2021 |
EXHIBIT 99.1 Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors LA JOLLA, Calif., March 9, 2021 - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamar |
|
| March 1, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0. |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 12, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| February 16, 2021 |
SC 13G/A 1 tm216476d23sc13ga.htm SCHEDULE 13G/A CUSIP No: 040448201 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Ti |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) |
|
| February 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 21, 2021 |
As filed with the Securities and Exchange Commission on January 20, 2021 Registration No. |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) ARTELO BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule purs |
|
| January 15, 2021 |
As filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| January 15, 2021 |
As filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| January 13, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 16, 2020 |
EXHIBIT 99.1 2018 EQUITY INCENTIVE PLAN ARTELO BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN (as amended December 3, 2020) 1.Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of the Company’s busi |
|
| December 16, 2020 |
Specimen Common Stock Certificate EXHIBIT 4.1 |
|
| December 16, 2020 |
As filed with the Securities and Exchange Commission on December 16, 2020 Registration No. |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 3, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| December 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2020 |
DEF 14A 1 artldef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑ |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-249083 Artelo Biosciences, Inc. |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| October 26, 2020 |
ARTL / Artelo Biosciences, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) KYG4645B1014 (CUSIP Number) October 14, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| October 22, 2020 |
ARTL / Artelo Biosciences, Inc. / ALPHA CAPITAL ANSTALT - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) ARTELO BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 (Title of Class of Securities) 04301G201 (CUSIP Number) October 14, 2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursua |
|
| October 19, 2020 |
ARTL / Artelo Biosciences, Inc. / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) |
|
| October 19, 2020 |
ARTL / Artelo Biosciences, Inc. / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04301G201 (CUSIP Number) October 14, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| October 19, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 16, 2020 with respect to the shares of Common Stock of Artelo Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) unde |
|
| October 15, 2020 |
ARTL / Artelo Biosciences, Inc. / CVI Investments, Inc. - SCHEDULE 13G Passive Investment CUSIP No: 040448201 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040448201 (CUSIP Numb |
|
| October 15, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) October 14, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| October 15, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04301G201 (CUSIP Number) October 9, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| October 14, 2020 |
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering EXHIBIT 99.1 Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering LA JOLLA, CA–October 9, 2020–Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced the pricing of an u |
|
| October 14, 2020 |
EXHIBIT 99.2 Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option LA JOLLA, Calif.–Oct. 14, 2020–Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, |
|
| October 14, 2020 |
EXHIBIT 1.1 Execution Copy 8,800,000 SHARES OF COMMON STOCK SERIES A WARRANTS EXERCISABLE INTO 8,800,000 SHARES OF COMMON STOCK OF ARTELO BIOSCIENCES, INC. UNDERWRITING AGREEMENT October 9, 2020 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 277 Park Avenue, 26th Floor New York, NY 10172 Ladies and Gentlemen: The undersigned, Art |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 9, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| October 14, 2020 |
EXHIBIT 4.2 Artelo Biosciences, Inc. and American Stock Transfer & Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of October 14, 2020 . WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of October 14, 2020 (“Agreement”), between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liab |
|
| October 13, 2020 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-249083 PROSPECTUS 8,800,000 Units Each Unit Consisting of One Share of Common Stock (par value $0.001 per share) and One Warrant to Purchase One Share of Common Stock This is an offering of 8,800,000 units of Artelo Biosciences, Inc., a Nevada Corporation (the “Units”). Each Unit consists of one (1) share of our common stock and one (1) warrant |
|
| October 9, 2020 |
As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 8, 2020 |
As filed with the Securities and Exchange Commission on October 8, 2020 Registration No. |
|
| October 7, 2020 |
Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, New York 10172 October 7, 2020 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: ARTELO BIOSCIENCES, INC. Registration Statement on Form S-1 (Registration No. 333-249083) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenburg Thalmann & Co. Inc. (“ |
|
| October 7, 2020 |
As filed with the Securities and Exchange Commission on October 6, 2020 Registration No. |
|
| October 7, 2020 |
Artelo Biosciences, Inc. 888 Prospect Street, Suite 210 La Jolla, California 92037 October 7, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Scott Anderegg Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 File No. 333-249083 Acceleration Request Requested Date: October 8, 2020 Requested Time: 5:30 p.m. Ea |
|
| October 6, 2020 |
Form of Lock-Up and Voting Agreement EXHIBIT 4.4 LOCK-UP AND VOTING AGREEMENT This Lock-Up and Voting Agreement (this “Lock-Up and Voting Agreement”) is being delivered to you in connection with an understanding by and between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby made to the public offering (the “ |
|
| October 6, 2020 | ||
| October 6, 2020 |
EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: [●] CUSIP: [●] ISIN: [●] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Charter Amendment Date |
|
| October 6, 2020 |
EXHIBIT 4.1 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE |
|
| October 6, 2020 |
Form of Underwriting Agreement EXHIBIT 1.1 [●] SHARES of Common Stock SERIES A Warrants exercisable into [●] shares of common stock OF ARTELO BIOSCIENCES, INC. UNDERWRITING AGREEMENT October [●], 2020 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 277 Park Avenue, 26th Floor New York, NY 10172 Ladies and Gentlemen: The undersigned, Artelo Biosciences, Inc., a |
|
| October 6, 2020 |
As filed with the Securities and Exchange Commission on October 6, 2020 Registration No. |
|
| September 28, 2020 |
As filed with the Securities and Exchange Commission on September 28, 2020 Registration No. |
|
| July 14, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235917 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated February 3, 2020) $2,249,412 Common Stock This prospectus supplement no. 3 relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $2,249,412, from time to time solely through Maxim Group LLC, as exclusive sale |
|
| July 14, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2020 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIENC |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 25, 2020 |
EX-99.1 4 artlex991.htm EQUITY INCENTIVE PLAN EXHIBIT 99.1 ARTELO BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN (as amended June 19, 2020) 1. Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of t |
|
| June 25, 2020 |
As filed with the Securities and Exchange Commission on June 25, 2020 Registration No. |
|
| June 22, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy Statement Def |
|
| April 21, 2020 |
CORRESP 1 filename1.htm April 21, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Scott Stringer Re: Artelo Biosciences, Inc. Form 10-K for the Fiscal Year Ended August 31, 2019 Response Dated March 27, 2020 File No. 1-38951 Dear Mr. Stringer, Artelo Biosciences, Inc. (the “Company”), is submitting this |
|
| April 15, 2020 |
EXHIBIT 1.1 Artelo Biosciences, Inc. Up to $3,000,000 of Shares of Common Stock Equity Distribution Agreement April 13, 2020 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 Ladies and Gentlemen: Artelo Biosciences, Inc., a Nevada corporation (the "Company"), proposes to issue and sell through Maxim Group LLC (the "Agent"), as sales agent, shares of common stock, par value $0.001 per |
|
| April 15, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| April 15, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235917 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated February 3, 2020) Up to $1,475,000 Common Stock This prospectus supplement number 2 and the accompanying base prospectus, which together we sometimes refer to as the prospectus, relate to the offer and sale, from time to time, of shares of our common stock, par value $0.001 per share, havi |
|
| April 14, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235917 PROSPECTUS SUPPLEMENT (to Prospectus dated February 3, 2020) $3,000,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $3.0 million, from time to time solely through Maxim Group LLC, as exclusive sales agent (w |
|
| April 13, 2020 |
ARTL / Artelo Biosciences, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 29, 2020 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| April 7, 2020 |
ARTL / Artelo Biosciences, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on April 6, 2020 Registration No. |
|
| March 27, 2020 |
March 27, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Scott Stringer Re: Artelo Biosciences, Inc. Form 10-K for the Fiscal Year Ended August 31, 2019 Filed on November 25, 2019 File No. 1-38951 Dear Mr. Stringer, Artelo Biosciences, Inc. (the “Company”), is submitting this letter in response to comme |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2020 |
KNKX / Knight Knox Development Corp. / O'Brien Peter Michael - SC 13G Passive Investment SC 13G 1 artlsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04301G 201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 14, 2020 |
KNKX / Knight Knox Development Corp. / Gorgas Gregory D. - FORM 13-G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04301G 201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2020 |
KNKX / Knight Knox Development Corp. / Moss David J - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04301G 201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| February 3, 2020 |
ARTL / Artelo Biosciences, Inc. CORRESP - - February 3, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Katherine Bagley Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on January 15, 2020 File No. 333-235917 Acceleration Request Requested Date: February 3, 2020 Requested Time: 2:00 P.M. Eastern Time Ladies and Gentlemen: Pur |
|
| January 15, 2020 |
KNKX / Knight Knox Development Corp. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on January 14, 2020 Registration No. |
|
| January 15, 2020 |
KNKX / Knight Knox Development Corp. S-3 - - FORM S-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑3 REGISTRATION STATEMENT Under The Securities Act of 1933 Artelo Biosciences, Inc. (Exact name of Registrant as specified in its charter) Nevada 33-1220924 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 888 Prospect Street, Suite 210 La Jolla, CA 92037 (760) 943-16 |
|
| January 15, 2020 |
EXHIBIT 4.1 |
|
| January 14, 2020 |
KNKX / Knight Knox Development Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| January 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| January 14, 2020 |
EXHIBIT 10.3 ARTELO BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 30, 2019, and is effective as of June 20, 2019 (the “Effective Date”) by and between Artelo Biosciences, Inc. (the “Company”), and Gregory D. Gorgas (“Executive”). WHEREAS, Executive previously entered into an Employment Agree |
|
| January 14, 2020 |
EXHIBIT 99.1 ARTELO BIOSCIENCES REPORTS FIRST QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE LA JOLLA, CA – January 14, 2020 – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the first quarter of its fis |
|
| January 3, 2020 |
KNKX / Knight Knox Development Corp. / Alinga Capital Llc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Artelo Biosciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04301G102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| December 19, 2019 |
KNKX / Knight Knox Development Corp. CORRESP - - December 19, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Daniel Morris Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on November 25, 2019 File No. 333-234372 Acceleration Request Requested Date: December 20, 2019 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pur |
|
| December 19, 2019 |
KNKX / Knight Knox Development Corp. CORRESP - - CORRESP 1 filename1.htm December 19, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Daniel Morris Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on December 18, 2019 File No. 333-232853 Acceleration Request Requested Date: December 20, 2019 Requested Time: 4:00 P.M. Eastern Time L |
|
| December 19, 2019 |
KNKX / Knight Knox Development Corp. S-3/A - - FORM S-3 AMENDMENT NO. 2 As filed with the Securities and Exchange Commission on December 18, 2019 Registration No. |
|
| December 18, 2019 |
KNKX / Knight Knox Development Corp. 10-K/A - Annual Report - FORM 10-K AMENDMENT NO. 1 10-K/A 1 artl10ka.htm FORM 10-K AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio |
|
| December 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-234372 Artelo Biosciences, Inc. |
|
| November 25, 2019 |
EXHIBIT 10.3 ARTELO BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 30, 2019, and is effective as of June 20, 2019 (the “Effective Date”) by and between Artelo Biosciences, Inc. (the “Company”), and Gregory D. Gorgas (“Executive”). WHEREAS, Executive previously entered into an Employment Agree |
|
| November 25, 2019 |
KNKX / Knight Knox Development Corp. S-3/A - - FORM S-3 AMENDMENT NO. 1 S-3/A 1 artls3a1.htm FORM S-3 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on November 25, 2019 Registration No. 333-232853 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S‑3 REGISTRATION STATEMENT Under The Securities Act of 1933 Artelo Biosciences, Inc. (Exact name of Registrant as specified in its charter) Nevada 33-1220924 (State or ot |
|
| November 25, 2019 |
KNKX / Knight Knox Development Corp. S-3/A - - FORM S-3 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on November 25, 2019 Registration Nos. |
|
| November 15, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| November 15, 2019 |
EXHIBIT 99.1 |
|
| November 12, 2019 |
KNKX / Knight Knox Development Corp. CORRESP - - November 12, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Attention: Daniel Morris Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on October 30, 2019 File No. 333-234372 Withdrawal of Acceleration Request Dear Mr. Morris: Artelo Biosciences, Inc. (the “Company”) hereby respectfully requests withdrawal of its accel |
|
| November 8, 2019 |
KNKX / Knight Knox Development Corp. CORRESP - - November 8, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Daniel Morris Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on October 30, 2019 File No. 333-234372 Acceleration Request Requested Date: November 12, 2019 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursu |
|
| October 30, 2019 |
KNKX / Knight Knox Development Corp. S-3 - - FORM S-3 S-3 1 artls3.htm FORM S-3 As filed with the Securities and Exchange Commission on October 29, 2019 Registration Nos. 333-222756 333-227571 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S–1 ON FORM S‑3 REGISTRATION STATEMENT Under The Securities Act of 1933 Artelo Biosciences, Inc. (Exact name of Registrant as specified in its charter) Nevada 33-12 |
|
| September 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2019 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2019 |
EXHIBIT 10.19 CONSULTING AGREEMENT This Consulting Agreement (this "Agreement") is entered into effective as of 1st April 2018 by and between Artelo Biosciences, Inc. and Blackrock Ventures Ltd (the "Company"), Peter O'Brien ("Consultant"). 1. Services. During the term of this Agreement, Consultant will provide consulting services (the "Services") to the Company as described on Exhibit A attached |
|
| July 26, 2019 |
KNKX / Knight Knox Development Corp. S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on July 26, 2019 Registration No. |
|
| July 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2019 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| July 15, 2019 |
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update EXHIBIT 99.1 Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update LA JOLLA, CA–July 15, 2019–Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corpora |
|
| July 15, 2019 |
KNKX / Knight Knox Development Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38951 ARTELO BIOSCIENCES |
|
| June 25, 2019 |
Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq EXHIBIT 99.1 Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq LA JOLLA, Calif. – June 21, 2019 – Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system, today announced the pricing of its publ |
|
| June 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2019 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| June 25, 2019 |
EX-99.2 4 artlex992.htm EX-99.2 EXHIBIT 99.2 Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option LA JOLLA, Calif. – June 25, 2019 – Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting t |
|
| June 25, 2019 |
EXHIBIT 3.1 |
|
| June 25, 2019 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-230658 ARTELO BIOSCIENCES, INC. 1,300,813 Units Each Unit Consisting of One Share of Common Stock (par value $0.001 per share) and One Warrant to Purchase One Share of Common Stock This is a firm commitment public offering of 1 , 300,813 units of Artelo Biosciences, Inc., a Nevada Corporation (the “Units”). Each unit consists of one (1) share o |
|
| June 20, 2019 |
KNKX / Knight Knox Development Corp. 8-A12B - - 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. (Exact name of Registrant as specified in its charter) Nevada 33-1220924 (State of incorporation or organization) (I.R.S. Employer Identification No.) 888 Prospect Street, |
|
| June 20, 2019 |
EXHIBIT 3.5 |
